Skip to main content

Table 3 Aminoglycoside therapy characteristics

From: An international survey on aminoglycoside practices in critically ill patients: the AMINO III study

  All (n = 931) Amikacin (n = 614) Gentamicin (n = 303) Tobramycin (n = 14)
Duration of therapy (days) 2 [1; 3] 2 [1; 3] 2 [1; 3] 2 [2; 4.75]
Number of injections 2 [1; 2] 2 [1; 2] 2 [1; 2] 2 [1; 4]
Second dose administered 483 (52%) 326 (53%) 164 (53%) 13 (93%)
First dose in mg 2000 [1500; 2250] 440 [320; 560] 500 [381; 555]
First dose in mg per kg of TBW 26 [21.9; 29.4] 5.6 [4.3; 7.5] 6 [5.1; 7.1]
First dose in mg per kg of ABW 267.8 [23.8; 29.4] 6.2 [4.8; 7.8] 6.1[5.4; 7.1]
Infusion duration (min) 30 [30; 30] 30 [30; 30] 30 [30; 30] 30 [30; 30]
Cmax after first dose 437/931 (47%) 341/614 (56%) 90/303 (30%) 6/14 (43%)
Cmax value (mg L−1) 73 [57; 90] 21 [17; 25] 19 [14; 26]
Delay end of infusion and Cmax sampling (min) 30 [30; 50] 30 [30; 50] 30 [30; 44] 30 [26; 37]
Targeted Cmax attainment after first dose 295/437 (68%) 241/341 (71%) 53/90 (59%) 1/6 (17%)
Cmin after first dose 501/880 (57%) 347/577 (60%) 145/289 (50%) 6/14 (43%)
Cmin above threshold 353/498 (71%) 230/347 (66%) 118/145 (81%) 5/6 (83%)
Time from first dose to Cmin (h) 22.9 [20.4; 24] 22.6 [20.5; 24] 23.4 [21.5; 24.1] 24.4 [23.6; 26.1]
Interval after first dose (h) 26 [23; 43] 26.7 [23; 45] 24.8 [23; 34] 24.5 [23; 29]
  1. For continuous variables, mean ± standard deviation or median [interquartile range] are given. For categorical variables, numbers (%) are given. The ABW was calculated as follow: IBW + 0.4 x (TBW-IBW). The Cmax attainment is defined as a Cmax above 20 mg L−1 for gentamicin and tobramycin or above 60 mg L−1 for amikacin. The Cmin thresholds considered are 0.5 mg L−1 for gentamicin and tobramycin and 2.5 mg L−1 for amikacin
  2. Cmax: maximal concentration; Cmin: minimal concentration; ABW: adjusted body weight, TBW: total body weight; IBW: ideal body weight
\